Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Mol Diagn Ther. 2017 Dec;21(6):621–631. doi: 10.1007/s40291-017-0292-x

TABLE 2.

Drug transport variants that influence TKI response in CML patients

Genes Variants Drugs References
ABCB1 1263 (TT), (CT/TT)
2677 (TT/TA), (G)
3435 (TT), (CC)
Imatinib [5053]
ABCG2 34 (G>A)
421 (C>A)
Imatinib
Dasatinib
Nilotinib
[65, 66]
SLC22A1 rs3798168,
rs628031
IVS7+850 (C>T)
480 (C>G)
401 (G/A)
Imatinib [7274]
SLC22A4 rs1050152 Imatinib [80]
SLCO1A2 361 (GG) Imatinib [78]
SLCO1B3 334 (GG), (TT)
699 (GG)
Imatinib [77, 79]
ABCA3 4548–91 (CC/CA) Imatinib [79]